What is the recommended management for chronic kidney disease?

Management of Chronic Kidney Disease (CKD)

Modern CKD management centers on a multi-drug approach using SGLT2 inhibitors, RAS inhibitors, and nonsteroidal mineralocorticoid receptor antagonists, with treatment intensity guided by eGFR and albuminuria levels.

Core Pharmacologic Strategy

The 2024 KDIGO guidelines establish a clear therapeutic hierarchy for CKD management 1:

1. SGLT2 Inhibitors (First-Line for Most Patients)

SGLT2 inhibitors should be initiated in virtually all CKD patients with eGFR ≥20 mL/min/1.73 m², regardless of diabetes status 1:

• Strong indication (1A): Type 2 diabetes with eGFR ≥20 mL/min/1.73 m²
• Strong indication (1A): eGFR ≥20 mL/min/1.73 m² with ACR ≥200 mg/g OR heart failure (any albuminuria level)
• Moderate indication (2B): eGFR 20-45 mL/min/1.73 m² with ACR <200 mg/g

Key management points:

• Continue SGLT2i even if eGFR drops below 20 mL/min/1.73 m² after initiation 1
• Temporarily withhold during prolonged fasting, surgery, or critical illness (ketosis risk) 1
• The initial eGFR dip is expected and not a reason to stop therapy 1

2. RAS Inhibitors (ACEi or ARB)

Use maximum tolerated doses - the proven benefits in trials were achieved at highest approved doses 1:

Indications by albuminuria:

• Moderately-to-severely increased albuminuria (A2-A3) with diabetes: Strong recommendation (1B) 1
• Moderately-to-severely increased albuminuria (A2-A3) without diabetes: Weaker recommendation (2C) 1
• Normal/mildly increased albuminuria (A1): Consider for hypertension or heart failure with reduced ejection fraction 1

Monitoring protocol:

• Check BP, creatinine, and potassium within 2-4 weeks of initiation or dose increase 1
• Continue therapy unless creatinine rises >30% within 4 weeks 1
• Continue even when eGFR falls below 30 mL/min/1.73 m² 1

Managing complications:

• Hyperkalemia: Treat the hyperkalemia first (potassium binders, dietary modification) rather than stopping RASi 1
• Only reduce/stop for: Symptomatic hypotension, uncontrolled hyperkalemia despite treatment, or uremic symptoms with eGFR <15 mL/min/1.73 m² 1

3. Nonsteroidal Mineralocorticoid Receptor Antagonists (nsMRA)

Add nsMRA (like finerenone) for patients with persistent albuminuria despite RASi and SGLT2i 1:

Criteria for use (2A recommendation):

• Type 2 diabetes
• eGFR >25 mL/min/1.73 m²
• Normal serum potassium
• Albuminuria >30 mg/g despite maximum tolerated RASi dose

This represents triple therapy: RASi + SGLT2i + nsMRA for high-risk patients with persistent albuminuria 1

Blood Pressure Management

Target BP <140/90 mm Hg for all CKD patients, with systolic target ≤120 mm Hg for those tolerating therapy 2. Use ACEi or ARB as first-line agents 2.

Additional Metabolic Management

For Type 2 Diabetes with CKD:

• SGLT2 inhibitors (primary agent) 1
• GLP-1 receptor agonists for additional glycemic control and cardiovascular benefit 3, 4
• Metformin can be continued in CKD 2

Cardiovascular Risk Reduction:

• Statins for cardiovascular risk reduction 3, 5

Monitoring and Complications

Regular monitoring for CKD complications 5:

• Hyperkalemia
• Metabolic acidosis
• Hyperphosphatemia
• Vitamin D deficiency and secondary hyperparathyroidism
• Anemia (see anemia-specific guidelines 6)

Nephrology Referral Criteria

Refer promptly when 5:

• eGFR <30 mL/min/1.73 m²
• Albuminuria ≥300 mg per 24 hours
• Rapid eGFR decline
• Difficult-to-control complications

Critical Pitfalls to Avoid

1. Don't stop RASi or SGLT2i for modest creatinine increases - these are often hemodynamic and expected 1
2. Don't underdose RASi - use maximum tolerated doses for proven benefit 1
3. Don't reflexively stop RASi for hyperkalemia - treat the potassium first 1
4. Avoid nephrotoxins - NSAIDs, unnecessary contrast studies in advanced CKD 5, 2
5. Adjust drug dosing - many antibiotics and oral hypoglycemics require dose adjustment 5

Algorithmic Approach

Step 1: Confirm CKD diagnosis (eGFR <60 mL/min/1.73 m² or albuminuria ≥30 mg/g for >3 months)

Step 2: Initiate SGLT2 inhibitor if eGFR ≥20 mL/min/1.73 m²

Step 3: Add RASi (ACEi or ARB) at maximum tolerated dose if:

• Albuminuria A2-A3 (especially with diabetes), OR
• Hypertension, OR
• Heart failure with reduced ejection fraction

Step 4: If albuminuria persists >30 mg/g despite Steps 2-3 AND patient has type 2 diabetes with eGFR >25 mL/min/1.73 m² and normal potassium: Add nonsteroidal MRA

Step 5: Add statin for cardiovascular protection

Step 6: Monitor and manage complications; refer to nephrology when eGFR <30 mL/min/1.73 m² or rapidly declining

This evidence-based approach, grounded in the 2024 KDIGO guidelines 1, represents a paradigm shift from historical supportive care to aggressive disease modification that reduces both kidney disease progression and cardiovascular mortality 7, 4.